On Tuesday, September 21, Krishna Ella, managing director of the Hyderabad-based pharmaceutical company, told the reporters that Bharat Biotech has completed its Phase 2/3 trials of COVID-19 vaccine, Covaxin, on children below 18 years of age.
While addressing the media, he said that the production of Covaxin would touch 55 million doses in October. The output of Covaxin was 35 million in September.
He also mentioned that the number of volunteers is touching 1000 and data analysis is still ongoing. He would submit the data to the regulator by next week.
The firm's Phase 2 trials of the intranasal COVID-19 vaccine is expected to be completed by next month, said Ella.
The nose is the entry point for the virus, and intranasal immunization creates an immune response in the nose. It will protect the individual against the disease and its transmission, he added.
He said that the intranasal vaccine trials were regulated on three cohorts. One group was given Covaxin as the first dose and intranasal as the second dose. In the same way, another group was assigned intranasal-intranasal, and the third group was administered intranasal-Covaxin, 28 days apart.
As per reports, to increase the production of COVID-19 vaccination, Bharat Biotech has partnered with Indian Immunologicals and Hester Biosciences.
While mentioning the exports of Covaxin overseas, he said that if the centre allows, the firm is ready to export the jab; however, they are not in a hurry to transport it to other countries. Currently, the government is focusing on fulfilling domestic needs.
A few days ago, World Health Organization (WHO) was expected to give an emergency nod to Covaxin.
Share
Tweet
